(Q30983921)

28 June 2017

title

Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data (English)

1 reference

28 June 2017

main subject

kidney transplantation

1 reference

Marc I Lorber

1

1 reference

28 June 2017

Claudio Ponticelli

2

1 reference

28 June 2017

John Whelchel

3

1 reference

28 June 2017

Hartmut W Mayer

4

1 reference

28 June 2017

John Kovarik

5

1 reference

28 June 2017

Yulan Li

6

1 reference

28 June 2017

Heinz Schmidli

7

1 reference

28 June 2017

language of work or name

1 reference

1 April 2005

1 reference

28 June 2017

published in

Clinical Transplantation

1 reference

28 June 2017

volume

19

1 reference

28 June 2017

issue

2

1 reference

28 June 2017

page(s)

145-152

1 reference

Risk factors for late kidney allograft failure

28 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00326.X

Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00326.X

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00326.X

Early clinical experience with a novel rapamycin derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00326.X

Neoral use in the renal transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00326.X

Impact of acute rejection on development of chronic rejection in pediatric renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00326.X

RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00326.X

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00326.X

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00326.X

Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00326.X

Monitoring of mycophenolic acid in clinical transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00326.X

Pharmacokinetics of an Everolimus-Cyclosporine Immunosuppressive Regimen Over the First 6 Months After Kidney Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00326.X

HLA Points Assigned in Cadaveric Kidney Allocation Should Be Revisited: An Analysis of HLA Class II Molecularly Typed Patients and Donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00326.X

10.1111/J.1399-0012.2005.00326.X

21 January 2018

Identifiers

DOI

1 reference

28 June 2017

1 reference